Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- No Consensus on Flu Vaccines’ Efficacy against COVID-19: NIID Chief
November 12, 2020
- Japan to Give Ultracold Chain-Required COVID-19 Shots to Certain People in Short Period: Minister
November 12, 2020
- Lower House Health Committee Starts Debate on Immunization Bill; Minister Says to Publish PAFSC Meeting Minutes ASAP
November 12, 2020
- Chuikyo’s Drug Pricing Subcommittee to Meet after 4-Month Hiatus to Discuss Off-Year Re-Pricing, Hear Industry Views
November 12, 2020
- Chuikyo Payer Rep Calls for Cost-Effectiveness Assessment of Drugs Used Together with Medical Devices
November 12, 2020
- Japan’s 1st Therapeutic App OK’ed for Health Coverage, Due for Release on Dec. 1
November 12, 2020
- LDP Lawmakers Leery of Off-Year Drug Re-Pricing to Meet on Nov. 26
November 11, 2020
- PM Suga Vows Transparency in COVID-19 Vaccine Review as Immunization Bill Enters Diet Deliberations
November 11, 2020
- Oral Semaglutide, Gilead JAK Inhibitor, Takeda’s PARP Med OK’ed for Listing on Nov. 18
November 11, 2020
- MHLW Says to Publish PAFSC Minutes for COVID-19 Vaccines in 3 Weeks, but Opposition Parties Unimpressed
November 10, 2020
- Public-Private Confab Set for November 16; Pro-Innovation Measures Up for Discussion
November 10, 2020
- Japan to Set New Technical Fee for CureApp’s Quit Smoking App
November 10, 2020
- MHLW Unveils Draft Ordinance for Electronic Distribution of Package Inserts; Use of GS1 Codes Expected
November 10, 2020
- Swiftly Disclose PAFSC Minutes for COVID-19 Vaccines: Opposition Parties
November 9, 2020
- MHLW to Appropriately Handle FY2021 Off-Year Re-Pricing Debate: Minister
November 9, 2020
- MHLW Won’t Exclude Software Programs from Conditional Approval Coverage: Official
November 6, 2020
- Bill to Amend Immunization Act to Enter Lower House Deliberations on November 10
November 6, 2020
- Package Insert Revisions Ordered for Opdivo, Copaxone
November 6, 2020
- Japan Trade Groups Renew Call for Cautious Discussions on Off-Year Re-Pricing: LDP Policy Confab
November 5, 2020
- LDP’s Fiscal Consolidation Panel Calls for Full Implementation of Off-Year Re-Pricing: Interim Report
November 5, 2020
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…